Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$11.08+0.18 (+1.65%)
Close on Nov 18, 2026Market cap $2.42BP/E –Yield –
Neogen operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Neogen's operating cash flow for the twelve months ending Aug 31, 2026 was $85.30M, down 1.9% year over year. For fiscal 2026 it was $83.20M, up 43.0% from the year before. Over ten years it grew 8.9% a year on average. The highest annual figure on record is $85.88M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $83.20M | +43.0% |
| FY2025 | May 31, 2025 | $58.20M | +64.9% |
| FY2024 | May 31, 2024 | $35.30M | -14.0% |
| FY2023 | May 31, 2023 | $41.03M | -39.7% |
| FY2022 | May 31, 2022 | $68.04M | -16.1% |
| FY2021 | May 31, 2021 | $81.09M | -5.6% |
| FY2020 | May 31, 2020 | $85.88M | +34.5% |
| FY2019 | May 31, 2019 | $63.84M | -7.7% |
| FY2018 | May 31, 2018 | $69.13M | +14.7% |
| FY2017 | May 31, 2017 | $60.27M | +70.6% |
| FY2016 | May 31, 2016 | $35.33M | -19.3% |
| FY2015 | May 31, 2015 | $43.79M | +102.1% |
| FY2014 | May 31, 2014 | $21.67M | -18.4% |
| FY2013 | May 31, 2013 | $26.56M | +19.2% |
| FY2012 | May 31, 2012 | $22.28M | -22.8% |
| FY2011 | May 31, 2011 | $28.84M | +3.1% |
| FY2010 | May 31, 2010 | $27.99M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $12.90M | +19.4% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $30.20M | +84.1% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $22.70M | +16.7% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $19.50M | -51.6% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $10.80M | – |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $16.40M | -38.8% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $19.46M | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $40.25M | +156.2% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -$17.91M | -177.9% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $26.78M | -70.6% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$30.21M | – |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $15.71M | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $23.01M | – |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $90.97M | +346.1% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -$17.07M | -359.0% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$18.73M | -204.9% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -$14.14M | -160.9% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $20.39M | -7.2% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $6.59M | -43.2% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $17.85M | -20.3% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $23.21M | -7.7% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $21.97M | -14.3% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $11.60M | -41.4% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $22.39M | +33.6% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $25.13M | +6.0% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $25.63M | +22.8% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $19.78M | +90.5% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $16.75M | +1.5% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $23.72M | +47.5% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $20.88M | -7.4% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $10.38M | -45.8% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $16.50M | +88.9% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $16.08M | -13.9% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $22.56M | +49.5% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $19.17M | +22.6% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $8.74M | -5.8% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $18.67M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $15.09M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $15.64M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $9.27M | – |
See a number that looks wrong?